Description

Simple

Clinical

Overview

Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

Pharmacology

Indication

For the treatment of various forms of cancer.

Pharmacodynamic

Information currently not available.

Mechanism of action

Ranpirnase controls tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1)phase.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Ranpirnase
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranpirnase.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ranpirnase.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ranpirnase.
Peginesatide
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ranpirnase.
7 References
  1. 1 . Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM: A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001;19(3):255-60.PubMed: 11561684
  2. 2 . Pavlakis N, Vogelzang NJ: Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 2006 Apr;6(4):391-9.PubMed: 16548765
  3. 3 . Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4.PubMed: 17324010
  4. 4 . Lee I, Kalota A, Gewirtz AM, Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007 Jan-Feb;27(1A):299-307.PubMed: 17352247
  5. 5 . Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo. 2007 Sep-Oct;21(5):721-8.PubMed: 18019404
  6. 6 . Suhasini AN, Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 2006 May 5;281(18):12201-9. Epub 2006 Feb 23.PubMed: 16497678
  7. 7 . Link Link